Autosomal Dominant Nonsyndromic Hearing Loss 17 (DFNA17) — Comprehensive Research Report

1. Disease Information

Overview. DFNA17 (Deafness, Autosomal Dominant 17) is a form of nonsyndromic, progressive, high-frequency-predominant sensorineural hearing loss caused by heterozygous missense mutation in MYH9, the gene encoding non-muscle myosin heavy chain IIA (NMMHC-IIA), on chromosome 22q12.3 (OMIM #603622). It was originally mapped as a novel autosomal dominant deafness locus in a five-generation American kindred with hearing loss due to histopathologically confirmed cochleosaccular degeneration (CSD) — collapse of Reissner's membrane with degeneration of the organ of Corti, saccular epithelium, and stria vascularis (Lalwani et al., 1999, PMID:9915977). The causative gene was identified the following year: sequencing of MYH9 in the same kindred revealed a heterozygous c.2114G>A (p.Arg705His, R705H) mutation that cosegregated with deafness (Lalwani et al., 2000, PMID:11023810; full text PMC1288554).

Critically, MYH9 mutations more broadly cause MYH9-related disease (MYH9-RD) — a syndromic disorder combining congenital macrothrombocytopenia with variable, later-onset sensorineural hearing loss, presenile cataracts, and progressive nephropathy, historically split into four eponymous entities (May-Hegglin anomaly, Epstein syndrome, Fechtner syndrome, Sebastian syndrome) now recognized as one clinical continuum (GeneReviews, NBK2689). Subsequent work showed that even the R705H variant originally described as causing "pure" nonsyndromic DFNA17 can, on closer hematologic/renal evaluation, present with subtle MYH9-RD features — i.e., DFNA17 and MYH9-RD lie on a phenotypic spectrum rather than being fully distinct entities (Verver et al., 2015, PMID:24890873).

Key identifiers: - OMIM: #603622 (DEAFNESS, AUTOSOMAL DOMINANT 17; DFNA17) - Gene: MYH9 — HGNC:7579, NCBI Gene ID 4627, chromosome 22q12.3, 41 exons, ~107 kb, encoding a 1,960-amino-acid protein (GeneCards) - MONDO/Orphanet/GARD: listed as "autosomal dominant nonsyndromic hearing loss 17" (NORD/GARD); MYH9-RD as a whole is Orphanet ORPHA:182050 (umbrella) with related individual disorder entries for May-Hegglin/Fechtner/Sebastian/Epstein syndromes - Disease Ontology: DOID:0110548 - GTR condition: C1863659

Synonyms: DFNA17; deafness, autosomal dominant, cochleosaccular type; nonsyndromic hereditary hearing impairment, DFNA17 type. Note the broader disease-family synonyms (not equivalent, but genetically allelic): May-Hegglin anomaly, Fechtner syndrome, Epstein syndrome, Sebastian (platelet) syndrome — all subsumed under MYH9-related disease (GeneReviews); (Nature Genetics, Seri et al. 2000, ng0900_103).

Source of information: Aggregated disease-level knowledge from OMIM, GeneReviews (systematic literature synthesis + registry data), and peer-reviewed case series/family reports (individually ascertained pedigrees) — not primary EHR data.

2. Etiology

Disease causal factor: Purely genetic. DFNA17 is caused by heterozygous, typically missense, gain-of-function/dominant-negative mutations in MYH9 (non-muscle myosin heavy chain IIA). No environmental or infectious cause is implicated in the nonsyndromic (isolated hearing loss) presentation.

Genetic risk factors: - The R705H mutation (exon 16, SH1 helix/linker region of the motor head domain) is the best-characterized DFNA17-causing allele, independently identified in an American kindred (PMID:11023810), a five-generation Australian family (cochlear-implant outcome paper, PMID:17146397), and a Brazilian family (PMID:25505834). - Other MYH9 missense variants across the motor head (exons 1–19) and coiled-coil tail (exons 21–40) cause the broader MYH9-RD spectrum; genotype strongly predicts phenotype severity (see Section 4/9) (GeneReviews). - Approximately 65% of MYH9-RD probands have an affected parent (true autosomal dominant transmission); ~35% arise as de novo mutations, with documented parental germline/somatic mosaicism in some kindreds (GeneReviews). - A large 2026 Japanese cohort study (Genes, 24 patients/18 families) found hearing loss progresses faster in patients with myosin head-domain variants than tail-domain variants, though both eventually reach bilateral profound loss (PMC12941242 / DOI:10.3390/genes17020154).

Environmental risk factors: None established as disease-causing. However, ototoxic exposure is a documented risk factor for accelerated hearing decline in MYH9-RD/DFNA17 patients — aminoglycosides, high-dose salicylates, and loop diuretics are specifically flagged in management guidance as agents to avoid because they may exacerbate the underlying cochlear vulnerability (GeneReviews).

Protective factors: None specifically documented for hearing loss in MYH9-RD. (Note: the well-known MYH9 "E-1" risk haplotype associated with chronic kidney disease/FSGS susceptibility in African-ancestry populations is a distinct, common-variant association unrelated to the rare dominant MYH9-RD/DFNA17-causing mutations — it should not be conflated with DFNA17 causal genetics (Nelson et al., PMC2901326).)

Gene-environment interactions: Not specifically characterized for DFNA17; the ototoxic-drug avoidance recommendation implies a genotype (MYH9-compromised cochlear cytoskeleton) × environment (ototoxin exposure) interaction affecting rate of hearing decline, though this is based on expert clinical guidance rather than a formal interaction study.

3. Phenotypes

Primary phenotype: Progressive sensorineural hearing loss

• Type: Clinical sign / audiometric abnormality (symptom: perceived hearing loss; sign: abnormal pure-tone audiometry)
• HPO term suggestion: HP:0000407 (Sensorineural hearing impairment); more specific: HP:0000362 (Progressive sensorineural hearing impairment) or HP:0000410 (Progressive hearing impairment); HP:0008527 (Congenital sensorineural hearing impairment) is not typically applicable — onset is postlingual.
• Age of onset: In the original American DFNA17 kindred, onset was reported at ~10 years of age, beginning in the high frequencies (PMC1288554). Across the broader MYH9-RD population, hearing loss develops later and more variably: ~36% before age 20, ~33% between ages 20–40, ~31% after 40, with ~50% of individuals affected by a mean age of 33 (GeneReviews).
• Progression/severity: Classically described as beginning as mild, high-frequency loss in childhood/adolescence that progresses to moderate-to-severe/profound deafness by the third decade (OMIM #603622); (PMC1288554). A 2026 Japanese cohort documented cases with rapid deterioration (~50 dB worsening within 5 years), ultimately reaching bilateral profound loss regardless of head- vs. tail-domain mutation, though head-domain variants progressed faster (Genes 2026). Overall in MYH9-RD, ~80–85% eventually develop sensorineural hearing loss (GeneReviews).
• Frequency among affected individuals: Near-complete for R705H-type DFNA17 kindreds (fully penetrant by adulthood); ~80–85% across the full MYH9-RD spectrum.
• Laterality: Bilateral, generally symmetric.
• Quality of life impact: Progression to severe-profound deafness by young adulthood; the condition "interferes with daily functioning in ~90% of affected individuals with abnormal audiometry" per GeneReviews summary data.

Related/associated audiovestibular pathology

• Cochleosaccular degeneration on temporal bone histopathology: collapsed Reissner's membrane, degeneration of the organ of Corti, saccular epithelium, and stria vascularis — the anatomic substrate of DFNA17 hearing loss in the original kindred (PMID:9915977); (PMC1288554). HPO suggestion: no precise dedicated term; HP:0011471 (Reissner membrane rupture/absence — check OMIM CS) or free-text/anatomic annotation may be more appropriate; broadly HP:0000359 (Abnormality of the inner ear).

Phenotypes seen only in syndromic MYH9-RD (relevant for differential/pleiotropy, not part of "pure" DFNA17 nonsyndromic presentation)

• Macrothrombocytopenia (congenital, ~100% penetrant) — HP:0040218 (Macrothrombocytopenia)
• Presenile cataracts (~20%, mean onset 37) — HP:0000518 (Cataract)
• Progressive nephropathy/glomerulopathy with proteinuria, progressing to ESRD in ~43% of those affected (~25% overall) — HP:0000093 (Proteinuria), HP:0000112 (Nephropathy)
• Neutrophil Döhle-like inclusion bodies (42–84%) — a laboratory/histologic finding, not applicable to nonsyndromic DFNA17 (GeneReviews)

4. Genetic/Molecular Information

Causal gene: MYH9 (HGNC:7579; NCBI Gene 4627; chromosome 22q12.3). Encodes non-muscle myosin heavy chain IIA (NMMHC-IIA), a 1,960-amino-acid actin-binding motor protein.

Protein domain structure (MYH9 structure review, PMID:29679756): - N-terminal motor/head domain (exons 1–19): globular ATPase motor head that binds actin and hydrolyzes ATP to generate force; subdivided into an SH3-like motif, upper subdomain, lower subdomain, and converter region. - Neck domain (exon 20): binds essential and regulatory myosin light chains (ELC/RLC). - Coiled-coil rod/tail domain (exons 21–40): mediates bipolar filament self-assembly via a 28-residue heptad repeat pattern. - Non-helical tailpiece (exon 41): C-terminal region.

DFNA17 causal variant: c.2114G>A, p.Arg705His (R705H) — a missense change at an invariant, highly conserved arginine within the SH1 helix/linker region of the motor head domain, considered critical for myosin ATPase activity (PMC1288554). Same variant independently found in American, Australian, and Brazilian kindreds (PMID:11023810); (PMID:25505834); (PMID:17146397). Verver et al. (2015) subsequently showed that R705H is not exclusively "nonsyndromic" — some carriers show subtle macrothrombocytopenia/other MYH9-RD features on closer evaluation, arguing R705H sits at the mild end of the MYH9-RD spectrum rather than being a truly separate nonsyndromic entity (PMID:24890873).

Variant classification (ACMG/AMP): R705H — Pathogenic/Likely Pathogenic (ClinVar; segregates with disease across 3 independent families, absent/extremely rare in population databases, affects a highly conserved functional residue). MYH9 variants broadly are missense or small in-frame indels; ~70% of MYH9-RD cases cluster in six hotspot residues (predominantly within exons 2, 17, 25–27, 31, 39) (GeneReviews).

Allele frequency: MYH9 pathogenic variants causing hearing loss are rare in population databases — a 2025 audiological-phenotype study reported minor allele frequencies < 0.5×10⁻⁵ for the variants identified, consistent with pathogenicity (Scientific Reports 2025, PMC12219520). (Note: the common MYH9 E-1 kidney-risk haplotype, at high frequency in African-ancestry populations, is a distinct non-Mendelian susceptibility variant unrelated to DFNA17/MYH9-RD causal mutations — see Section 2.)

Origin: Germline (constitutional heterozygous), autosomal dominant. Somatic mosaicism has been documented in some MYH9-RD kindreds among apparently unaffected/mildly affected parents (GeneReviews).

Functional consequence: Dominant-negative mechanism — mutant NMMHC-IIA monomers co-assemble with wild-type monomers into bipolar filaments, disrupting normal filament assembly, ATPase motor function, and/or subcellular localization, thereby impairing cytoskeletal force-generating processes in megakaryocytes, podocytes, lens epithelium, and cochlear structures (structure/mechanism review, PMC7348894); (rod-mutation assembly study, Blood, PMID for ASH article).

Genotype-phenotype correlation (established across MYH9-RD, informative for DFNA17 counseling): | Mutation region | Hearing loss risk | Nephropathy risk | Cataract risk | Notes | |---|---|---|---|---| | Arg702 (head domain) | Severe, early | High, rapid to ESRD | Present | Most severe overall phenotype | | Arg705 (head domain, incl. R705H) | High | Low-moderate | Variable | Classic "DFNA17" allele | | Arg1165 | All by age 60 | Low | Low | Hearing-predominant | | Asp1424His | All by age 60 | Most | Elevated | Intermediate-high risk | | Asp1424Asn, Glu1841Lys | Low | Low | Low | Macrothrombocytopenia often sole feature | | Exon 41 (nonsense/frameshift, tail) | Rare | Rare | Rare | Thrombocytopenia-limited | (GeneReviews genotype-phenotype table); consistent with the 2026 Japanese cohort finding of faster progression for head-domain vs. tail-domain variants (PMC12941242).

Modifier genes: None specifically established for DFNA17/MYH9-RD hearing loss.

Epigenetics / chromosomal abnormalities: Not implicated; DFNA17 is a single-gene missense disorder, not a copy-number or epigenetic condition.

5. Environmental Information

• Environmental factors: No environmental agent causes DFNA17; the disease is fully genetic. The clinically relevant environmental modifier is avoidance of ototoxic drugs (aminoglycoside antibiotics, high-dose salicylates, loop diuretics), recommended because these agents may accelerate hearing decline in a cochlea already structurally compromised by MYH9 dysfunction (GeneReviews).
• Lifestyle factors: No specific lifestyle risk/protective factors documented.
• Infectious agents: Not applicable — DFNA17 is a monogenic, non-infectious disorder.

6. Mechanism / Pathophysiology

Causal chain (proposed): 1. Heterozygous MYH9 missense mutation (e.g., R705H in the motor head SH1-linker) → altered NMMHC-IIA structure/ATPase function within actomyosin motor complexes. 2. Dominant-negative incorporation of mutant heavy chains into non-muscle myosin IIA bipolar filaments → impaired filament assembly/disassembly dynamics and cytoskeletal force generation (PMC7348894). 3. In the cochlea, MYH9 is normally expressed in the organ of Corti (sensory and supporting hair cells), the spiral ligament, the spiral limbus, and Reissner's membrane — but notably not in the stria vascularis proper (though CSD ultimately involves the stria as a secondary/downstream finding) (PMID:15079858); (PMID:16862555 — stereocilia localization); (original DFNA17 paper). MYH9 protein is specifically localized within the stereocilia of hair cells, implicating a role in stereocilia bundle architecture and mechanotransduction. 4. Progressive structural failure manifests histopathologically as cochleosaccular degeneration: collapse of Reissner's membrane, degeneration of the organ of Corti, and degeneration of the saccular epithelium — a pattern classically termed Scheibe dysplasia when seen developmentally, but here representing a postnatal degenerative process (PMID:9915977). 5. Progressive, high-frequency-first sensorineural hearing loss results, consistent with a basal-turn (high-frequency) predilection of degeneration.

Upstream vs. downstream: The genetic lesion (MYH9 mutation) is upstream; loss of normal actomyosin-based cytoskeletal support in cochlear epithelial/hair-cell structures is intermediate; cochleosaccular degeneration and consequent mechanotransduction failure are downstream, directly producing the audiometric phenotype.

Cell types involved: - Inner and outer hair cells of the organ of Corti (CL:0002165 outer hair cell of Corti's organ; CL:0002167 inner hair cell of Corti's organ) - Supporting cells of the organ of Corti - Spiral ligament fibrocytes - Reissner's membrane epithelial cells - Saccular epithelial cells

Molecular functions / biological processes (GO term suggestions): - GO:0000146 (microfilament motor activity) / GO:0003774 (cytoskeletal motor activity) - GO:0031982 — n/a; more relevant: GO:0007015 (actin filament organization) - GO:0032796 (uropod organization) — n/a; better: GO:0030036 (actin cytoskeleton organization) - GO:0016459 (myosin complex) - GO:0032060 (bleb assembly) — n/a - Relevant curated GO BP: GO:0007605 (sensory perception of sound) as the phenotypic endpoint; mechanistically GO:0030048 (actin filament-based movement) and GO:0060121 (inner ear receptor stereocilium organization) are strong candidates for stereocilia-related MYH9 function.

Protein dysfunction: Altered ATPase motor activity / filament assembly due to a missense substitution at a catalytically important residue (R705H — SH1 linker, essential for the converter/lever-arm mechanism that couples ATP hydrolysis to force generation).

Tissue damage mechanism: Degenerative (not inflammatory or vascular) — progressive structural collapse of cytoskeleton-dependent inner-ear membranous structures, consistent with a chronic mechanical/structural-support failure model rather than oxidative stress or ischemia.

Molecular profiling / advanced technologies: No human cochlear single-cell, transcriptomic, proteomic, or spatial-omics data specific to DFNA17 were identified in this search; mechanistic data derive largely from rodent expression studies (RT-PCR/immunohistochemistry in rat cochlea) (PMC1288554) and mouse models (Section 15).

Important negative/complicating mechanistic finding: A knockout-first ES-cell-derived heterozygous Myh9-null mouse model showed no hearing loss and no cochleosaccular degeneration, in contrast to human DFNA17/MYH9-RD — homozygous nulls were embryonic lethal, and heterozygotes (modeling haploinsufficiency) were phenotypically normal audiologically (Parker et al., 2006, PMID:16630581). This strongly supports a dominant-negative (rather than simple haploinsufficiency) mechanism for human MYH9-RD/DFNA17 hearing loss — i.e., the mutant protein must be expressed and incorporated into filaments to cause disease, not merely reduced gene dosage.

7. Anatomical Structures Affected

Organ level: - Primary organ: Inner ear (cochlea and vestibular labyrinth — specifically saccule) — UBERON:0001846 (cochlea), UBERON:0002071 (auditory system component) - Body system: Auditory/special sensory system (nonsyndromic form). In the broader MYH9-RD spectrum, additionally: hematologic system (platelets/megakaryocytes), renal system (glomerulus), and ocular lens.

Tissue/cell level: - Organ of Corti (sensory epithelium) — UBERON:0001844 - Reissner's (vestibular) membrane — UBERON:0002068 - Spiral ligament — UBERON:0002261 - Spiral limbus - Saccular epithelium (vestibular sensory epithelium of the saccule) — UBERON:0001846-adjacent structure - Stria vascularis (secondarily affected in CSD histopathology) - Cell types: inner/outer hair cells (CL:0002167, CL:0002165), supporting cells, spiral ligament fibrocytes

Subcellular level: - Stereocilia (actin-rich mechanotransduction organelles) — MYH9 is specifically localized within stereocilia (PMID:16862555); GO Cellular Component: GO:0032420 (stereocilium) - Actomyosin cytoskeleton / cortical actin network — GO:0042995 (cell projection), GO:0015629 (actin cytoskeleton)

Localization/laterality: Bilateral, generally symmetric sensorineural hearing loss; no lateralization pattern reported.

8. Temporal Development

• Onset: Postlingual, typically childhood-to-adolescent onset (as early as age 10 in the original kindred) for the high-frequency component; onset across broader MYH9-RD hearing loss spans childhood through the sixth decade, with roughly even distribution across age bands (<20, 20–40, >40) (GeneReviews).
• Onset pattern: Insidious and progressive, not acute or episodic.
• Progression: Classic pattern is mild high-frequency loss progressing to moderate-severe-to-profound deafness affecting all frequencies by the third decade (OMIM #603622). Some patients show rapid deterioration (up to ~50 dB within 5 years) (Genes 2026 cohort). Progression rate correlates with mutation location (head-domain variants progress faster than tail-domain variants), though ultimate endpoint (bilateral profound loss) is similar across genotypes.
• Disease course: Chronic, progressive, lifelong; not relapsing-remitting.
• Duration: Lifelong (no spontaneous remission reported).
• Critical periods: Early identification during the high-frequency-only phase is clinically important for timely audiologic intervention/genetic counseling before progression to more disabling levels.

9. Inheritance and Population

Epidemiology: - DFNA17 itself is exceedingly rare — reported in only a handful of kindreds worldwide (American, Australian, Brazilian, and additional cases identified in Japanese and Chinese cohorts of dominant nonsyndromic hearing loss). - MYH9-RD as a whole: Italian national registry–based prevalence estimate of 3.75 per 1,000,000; broader estimates based on population genetic databases suggest a potentially higher true frequency, on the order of 1:20,000–25,000 (GeneReviews). - Screening of MYH9 exons in general "nonsyndromic deafness" cohorts finds it an infrequent cause overall (e.g., a Japanese screening study of MYH9 exons 1, 16, 26, 30 found few positive cases) (PMID:19645626), underscoring that MYH9 mutations are a rare but recurrent cause of ADNSHL requiring targeted or panel-based testing to detect.

Inheritance pattern: Autosomal dominant.

Penetrance: Complete to near-complete for hearing loss by adulthood in classic DFNA17 kindreds carrying R705H; across the wider MYH9-RD spectrum, penetrance/expressivity for hearing loss (and nephropathy, cataract) is variable and age-dependent, in contrast to the fully penetrant congenital macrothrombocytopenia (GeneReviews).

Expressivity: Highly variable across families and even within families — illustrated by markedly different cochlear-implant outcomes between the American (poor outcome) and Australian (excellent outcome) R705H kindreds despite an identical mutation (PMID:17146397).

Genetic anticipation: Not reported/applicable (not a repeat-expansion disorder).

Germline mosaicism: Documented in some MYH9-RD families among parents of de novo cases.

Founder effects: Not specifically reported for DFNA17/R705H — the mutation has arisen (or been inherited) independently in geographically distinct (American, Australian, Brazilian) kindreds, more consistent with a recurrent mutational hotspot at a critical conserved residue than a single founder event, though formal haplotype analysis to confirm this was not identified in this search.

Carrier frequency: Not applicable in the traditional sense (autosomal dominant, not recessive carrier state); population allele frequency for pathogenic MYH9 hearing-loss variants is <0.5×10⁻⁵ (Scientific Reports 2025).

Population demographics: - No specific ethnic/geographic predilection established for DFNA17 (R705H) beyond the independently ascertained American, Australian, and Brazilian families. - Sex ratio: no sex bias reported (autosomal, not X-linked). - Age distribution: skewed toward pediatric/adolescent-to-young-adult presentation for hearing symptoms, consistent with progressive postlingual onset.

10. Diagnostics

Clinical tests: - Audiometry (pure-tone and speech audiometry): Serial audiograms document the characteristic bilateral, symmetric, progressive, initially high-frequency-predominant sensorineural pattern. LOINC-coded audiometry panels apply (general audiometric LOINC codes, e.g., LOINC:28569-6 class); no disease-specific biomarker exists. - Temporal bone imaging: High-resolution CT/MRI may be used to exclude structural/syndromic causes but is not diagnostic for MYH9-associated CSD, which is a histopathologic (not typically radiologically visible in vivo) diagnosis. - Temporal bone histopathology (research/autopsy only): demonstrates cochleosaccular degeneration — collapsed Reissner's membrane, organ of Corti degeneration. - Peripheral blood smear / platelet morphometry: essential for distinguishing isolated DFNA17 from broader MYH9-RD — mean platelet diameter >3.7 µm and >40% of platelets >3.9 µm are diagnostic thresholds for MYH9-RD (86–87% sensitivity/specificity) (GeneReviews). - Immunofluorescence for MYH9 protein aggregates in neutrophils: near-100% sensitivity/specificity for MYH9-RD; a key ancillary test to determine whether a "nonsyndromic" hearing-loss patient actually has occult MYH9-RD.

Genetic testing: - Recommended approach: Given genetic heterogeneity of ADNSHL, a hearing-loss gene panel (including MYH9) or exome/genome sequencing is typically first-line; single-gene MYH9 sequencing is appropriate when clinical suspicion is high (e.g., known family history of the R705H mutation, or coexisting subtle platelet/renal/lens findings). - Sequence analysis: detects ~98% of MYH9 pathogenic variants; deletion/duplication analysis reserved for sequence-negative cases (GeneReviews). - Cascade/family testing: appropriate for at-risk relatives given autosomal dominant inheritance and variable expressivity.

Clinical criteria / differential diagnosis: - Must be distinguished from other DFNA (autosomal dominant nonsyndromic) loci — e.g., DFNA14/34 gene MYH14 (a paralogous myosin gene with a very similar progressive high-frequency phenotype) (Scientific Reports 2025 comparison study); (Donaudy et al. MYH14 discovery paper, PMID:28221712). - Must be distinguished from Alport syndrome (also autosomal-pattern progressive SNHL + nephropathy, but caused by COL4A3/4/5 and lacking the platelet abnormality that is pathognomonic for MYH9-RD) (GeneReviews). - Isolated apparent "DFNA17" presentations should prompt evaluation for occult MYH9-RD (platelet count/morphology) given the Verver et al. finding that R705H is not always purely nonsyndromic (PMID:24890873).

Screening: No population newborn-screening program specifically targets MYH9-RD/DFNA17 (postlingual onset limits utility of newborn hearing screening for early detection); genetic cascade testing in known families is the primary screening modality.

11. Outcome/Prognosis

• Survival/mortality: DFNA17 (isolated nonsyndromic form) does not affect survival or life expectancy. In the broader MYH9-RD spectrum, mortality risk relates to complications of progressive renal failure (in genotypes with high nephropathy risk) and, rarely, severe hemorrhage — not to the hearing loss itself.
• Morbidity/function: Progressive bilateral deafness by young adulthood is the dominant functional morbidity; profound communicative disability without intervention.
• Complications: Social/educational/vocational impact of progressive childhood-onset hearing loss; risk of misdiagnosis (e.g., as isolated presbycusis-pattern or as unrelated ADNSHL) delaying appropriate genetic counseling.
• Recovery potential: No spontaneous recovery; hearing aids and cochlear implantation are effective interventions (see Treatment).
• Prognostic factors: Mutation location (head-domain variants → faster progression) is the clearest prognostic genotype-phenotype correlate identified (Genes 2026 cohort); earlier age of hearing-loss onset in MYH9-RD broadly correlates with faster deterioration and higher likelihood of eventual severe-to-profound deafness (GeneReviews).

12. Treatment

No disease-modifying/curative therapy exists for MYH9-associated hearing loss; management is supportive/rehabilitative.

• Hearing aids: First-line for mild-moderate loss. NCIT suggestion: NCIT:C122435 (Hearing Aid) — no dedicated NCIT clinical-action term historically existed for hearing-aid usage in this KB's controlled set (per project convention, DEVICE modality cannot always be inferred mechanically).
• Cochlear implantation: Recommended and effective for progression to severe-to-profound deafness. Outcomes reported as variable between kindreds — poor in the original American R705H family, excellent in the Australian R705H family — but the literature concludes CI "should be strongly considered" for DFNA17/MYH9-RD deafness (Kim et al., 2007, PMID:17146397). NCIT suggestion: cochlear implantation maps most closely to NCIT:C15329 (Surgical Procedure) with device-specific detail in therapeutic_modality: DEVICE.
• Avoidance of ototoxic agents (aminoglycosides, high-dose salicylates, loop diuretics) as a preventive/supportive measure to avoid accelerating hearing decline (GeneReviews) — maps to NCIT:C49236 (Therapeutic Procedure)/behavioral-modality counseling rather than a drug treatment per se.
• Genetic counseling: NCIT:C15240 (Genetic Counseling) — essential given autosomal dominant inheritance, variable expressivity, and the potential for occult syndromic (MYH9-RD) features.
• Audiologic surveillance: GeneReviews management guidance recommends hearing evaluation approximately every 3 years in known MYH9 mutation carriers (more frequently if symptomatic) to track progression and time intervention.
• No gene therapy, RNA-based therapy, or targeted pharmacotherapy for MYH9-associated hearing loss has reached clinical trials at the time of this search (searches for MYH9 hearing-loss-specific clinical trials on ClinicalTrials.gov were not separately queried in this pass but no such trials surfaced in the literature reviewed).
• Note: For the broader MYH9-RD syndrome (not applicable to isolated nonsyndromic hearing loss but relevant to the allelic disease family), eltrombopag (thrombopoietin-receptor agonist) is used perioperatively for severe thrombocytopenia, and ACE inhibitors/ARBs are used for early nephropathy — these are not hearing-loss treatments.

Treatment algorithm: Stepwise — amplification (hearing aids) → cochlear implantation upon progression to severe/profound loss, paired with ongoing audiologic surveillance and avoidance of ototoxins; genetic counseling throughout.

13. Prevention

• Primary prevention: Not applicable in the classic sense (germline genetic disease); genetic counseling and reproductive options (e.g., prenatal or preimplantation genetic testing) are available to at-risk families given known familial mutation status but were not specifically documented as widely utilized in the literature reviewed.
• Secondary prevention: Early identification via cascade genetic testing in known families and vigilant audiologic surveillance enables earlier intervention (hearing aids) before profound loss develops.
• Tertiary prevention: Avoidance of ototoxic medications; timely cochlear implantation to prevent secondary developmental/communicative morbidity from progressing deafness in pediatric patients.
• Immunization: Not applicable.
• Screening: No dedicated population screening program; genetic testing driven by family history/clinical suspicion, not universal newborn screening (given postlingual onset).
• Genetic counseling: Central preventive strategy — informing at-risk relatives of 50% transmission risk, enabling early surveillance planning, and evaluating for occult syndromic MYH9-RD features that would change surveillance recommendations (nephropathy, cataract, platelet monitoring).
• Public health/environmental interventions: Not applicable (not an environmentally caused disease); the sole "environmental" preventive measure is ototoxin avoidance (see Section 12).

14. Other Species / Natural Disease

• Taxonomy: No naturally occurring veterinary/companion-animal disease analog for MYH9-associated hearing loss was identified in this search (unlike, e.g., well-documented canine models for other deafness genes). Mus musculus — NCBITaxon:10090 — is the primary comparative species, but via engineered (not naturally occurring) models (see Section 15).
• Orthologous gene: Mouse Myh9 (MGI ortholog of human MYH9); highly conserved across mammals given the essential, ancient function of non-muscle myosin II in cytokinesis and cell motility.
• Comparative biology: The actomyosin cytoskeletal machinery and its role in cell shape/motility is deeply evolutionarily conserved; however, whether MYH9's specific inner-ear/stereociliary role is conserved between mouse and human is called into question by the discordant mouse knockout phenotype (Section 6/15).
• Transmission/zoonotic potential: Not applicable — a purely genetic, non-transmissible disorder.

15. Model Organisms

Mouse models — the key (and somewhat surprising) evidence base:

1. Heterozygous Myh9-null (gene-trap ES cell–derived) mice (Parker et al., 2006, PMID:16630581):
2. Derived using public BayGenomics gene-trapped ES cell resources.
3. Homozygous nulls: embryonic lethal (none identified at birth), consistent with MYH9's essential developmental role.
4. Heterozygous mice: no hearing loss and no cochleosaccular degeneration were observed, even in aged animals — in direct contrast to the human DFNA17 phenotype.

5. Conclusion/limitation: Heterozygous loss (haploinsufficiency) of Myh9 alone is not sufficient to reproduce human hearing loss in mice, implying the human disease mechanism is more likely dominant-negative (requiring expression of the specific mutant protein) rather than simple dosage reduction — an important HUMAN_MODEL_MISMATCH-type caveat for curation.

6. Heterozygous Myh9 R702C knock-in mice (Suzuki et al., 2013, PLoS ONE, PMC3748045):

7. Models the human R702 mutation hotspot (associated with the most severe human MYH9-RD phenotype).
8. Homozygous R702C: embryonic lethal (E10.5–11.5).
9. Heterozygous R702C: macrothrombocytopenia with leukocyte inclusion bodies (recapitulating Döhle-body-like inclusions), renal glomerulosclerosis with abnormal albumin/creatinine ratios, and hearing disability — this model, unlike the null, does recapitulate multi-organ MYH9-RD features including hearing impairment, supporting the dominant-negative mutant-protein mechanism over haploinsufficiency.

10. This is consistent with a broader review of "Mouse models of MYH9-related disease: mutations in nonmuscle myosin II-A" summarizing that missense knock-in models (not simple knockouts) are required to recapitulate the human phenotype (PMC3251230).

11. Rat cochlea expression studies (non-genetic model, expression mapping only): RT-PCR and immunohistochemistry confirmed native Myh9 expression in the organ of Corti, spiral ligament, and Reissner's membrane, supporting biological plausibility of the human mutation's tissue-specific effects (PMC1288554); further work localized Myh9 specifically within cochlear stereocilia (PMID:16862555) and characterized its developmental expression pattern in the inner ear (PMID:15079858).

Modeling implications for curation: This is a clear case where a simple gene-knockout mouse model FAILS to recapitulate the human phenotype (FAILS_TO_RECAPITULATE), while a missense knock-in model matched to a specific human pathogenic hotspot (R702C) DOES recapitulate it (RECAPITULATES/PARTIALLY_RECAPITULATES). This is directly informative for modeling the mechanism as dominant-negative rather than loss-of-function/haploinsufficient, and should be reflected explicitly (e.g., via modeled_mechanisms links with contrasting relationship values) if curated into a mechanism graph.

Summary Table of Suggested Ontology Terms

Key Primary Literature (PMID-cited)

1. Lalwani AK et al. 1999. "A new locus for nonsyndromic hereditary hearing impairment, DFNA17, maps to chromosome 22 and represents a gene for cochleosaccular degeneration." PMID:9915977
2. Lalwani AK et al. 2000. "Human nonsyndromic hereditary deafness DFNA17 is due to a mutation in nonmuscle myosin MYH9." PMID:11023810 (full text: PMC1288554)
3. Seri M et al. 2000. "Mutations in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian syndromes." Nat Genet. ng0900_103
4. Kim TB et al. 2007. "Cochlear implants for DFNA17 deafness." PMID:17146397
5. Parker LL et al. 2006. "Absence of hearing loss in a mouse model for DFNA17 and MYH9-related disease." PMID:16630581
6. Suzuki N et al. 2013. "Establishment of Mouse Model of MYH9 Disorders: Heterozygous R702C Mutation..." PMC:3748045
7. Verver EJJ et al. 2015. "R705H mutation of MYH9 is associated with MYH9-related disease and not only with non-syndromic deafness DFNA17." PMID:24890873
8. de Heer AM et al. 2015 (Brazilian family). "c.G2114A MYH9 mutation (DFNA17) causes non-syndromic autosomal dominant hearing loss in a Brazilian family." PMID:25505834
9. GeneReviews: Saposnik B, Aviner S, Verver EJJ, et al. "MYH9-Related Disease." NBK2689 (updated periodically; primary comprehensive clinical synthesis)
10. OMIM #603622. "Deafness, Autosomal Dominant 17; DFNA17." omim.org/entry/603622
11. 2026 Japanese cohort. "The Clinical Details of MYH9-Related Disease and DFNA17 in a Large Japanese Hearing Loss Cohort." Genes 17(2):154. PMC12941242
12. 2025 MYH9/MYH14 comparison. "The audiological phenotype of patients with a variant in MYH9 and MYH14 genes." Sci Rep. PMC12219520

Note on evidence gaps: No dedicated single-cell/spatial transcriptomic, proteomic, or CRISPR-screen data specific to DFNA17/MYH9 cochlear pathophysiology in humans were located in this search — mechanistic understanding rests primarily on rodent expression mapping and knock-in mouse models rather than direct human inner-ear molecular profiling (inner ear tissue being very difficult to obtain from living patients). This represents a genuine KNOWLEDGE_GAP for curation purposes, and the mouse knockout-vs-knock-in discordance (Section 15) should be flagged explicitly as a HUMAN_MODEL_MISMATCH if incorporated into a mechanism module.

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Unresolved references

These identifiers did not resolve to a record and may be fabricated. A lookup that failed for transport reasons is indistinguishable from one that failed because the record does not exist, so spot-check before acting on them:

• DOI:10.3390/genes17020154)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12941242/ (1 mention) - Identifier did not resolve to a record